skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Combined treatment in carcinoma of the nasopharynx

Abstract

From October 1982 to August 1984, 30 previously untreated patients with biopsy-proven carcinoma of the nasopharynx, stage III (26.5%) and stage IV (73.5%), received combined radiotherapy (6,000 to 7,000 cGy over a period of 7 to 7.5 weeks) and chemotherapy (mitomycin-C 10 mg/M2, IV; 5-fluorouracil 750 mg/M2, IV; and methotrexate 30 mg/M2, IV) concomitantly. There were 20 males and 10 females, with a median age of 40 years. Minimal follow-up duration was 24 months. Actuarial overall survival rate at 48 months was 49%. Complete local response was achieved in 75% of the patients, with 31% of the cases failing distantly. The complication rate was high and included severe mucositis, xerostomia, and septicemia (fatal in two cases). Despite high local disease control, survival rate did not increase. A randomized trial is urgently needed to establish whether or not combined treatment is of value in advanced carcinoma of the nasopharynx.

Authors:
;
Publication Date:
Research Org.:
McGill Univ., Montreal, Quebec (Canada)
OSTI Identifier:
6923865
Resource Type:
Journal Article
Journal Name:
Laryngoscope; (United States)
Additional Journal Information:
Journal Volume: 98:8
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; COMBINED THERAPY; PHARYNX; FLUOROURACILS; METHOTREXATE; MITOMYCIN; PATIENTS; SURVIVAL CURVES; ANTI-INFECTIVE AGENTS; ANTIBIOTICS; ANTIMETABOLITES; ANTIMITOTIC DRUGS; ANTINEOPLASTIC DRUGS; AZINES; BODY; DIGESTIVE SYSTEM; DISEASES; DRUGS; HETEROCYCLIC COMPOUNDS; HYDROXY COMPOUNDS; NEOPLASMS; ORGANIC COMPOUNDS; ORGANIC FLUORINE COMPOUNDS; ORGANIC HALOGEN COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANS; PYRIMIDINES; RESPIRATORY SYSTEM; THERAPY; URACILS; 550603* - Medicine- External Radiation in Therapy- (1980-); 550600 - Medicine

Citation Formats

Souhami, L, and Rabinowits, M. Combined treatment in carcinoma of the nasopharynx. United States: N. p., 1988. Web. doi:10.1288/00005537-198808000-00018.
Souhami, L, & Rabinowits, M. Combined treatment in carcinoma of the nasopharynx. United States. https://doi.org/10.1288/00005537-198808000-00018
Souhami, L, and Rabinowits, M. 1988. "Combined treatment in carcinoma of the nasopharynx". United States. https://doi.org/10.1288/00005537-198808000-00018.
@article{osti_6923865,
title = {Combined treatment in carcinoma of the nasopharynx},
author = {Souhami, L and Rabinowits, M},
abstractNote = {From October 1982 to August 1984, 30 previously untreated patients with biopsy-proven carcinoma of the nasopharynx, stage III (26.5%) and stage IV (73.5%), received combined radiotherapy (6,000 to 7,000 cGy over a period of 7 to 7.5 weeks) and chemotherapy (mitomycin-C 10 mg/M2, IV; 5-fluorouracil 750 mg/M2, IV; and methotrexate 30 mg/M2, IV) concomitantly. There were 20 males and 10 females, with a median age of 40 years. Minimal follow-up duration was 24 months. Actuarial overall survival rate at 48 months was 49%. Complete local response was achieved in 75% of the patients, with 31% of the cases failing distantly. The complication rate was high and included severe mucositis, xerostomia, and septicemia (fatal in two cases). Despite high local disease control, survival rate did not increase. A randomized trial is urgently needed to establish whether or not combined treatment is of value in advanced carcinoma of the nasopharynx.},
doi = {10.1288/00005537-198808000-00018},
url = {https://www.osti.gov/biblio/6923865}, journal = {Laryngoscope; (United States)},
number = ,
volume = 98:8,
place = {United States},
year = {Mon Aug 01 00:00:00 EDT 1988},
month = {Mon Aug 01 00:00:00 EDT 1988}
}